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Abstract
The relationship between sleep disorders and bronchiectasis has not been well described.
We hypothesize that, due to the irreversible dilatation of the bronchi, the presence of secre-
tions, and airflow obstruction, patients with non-cystic fibrosis bronchiectasis may be predis-
posed to hypoxemia during sleep, or to symptoms that may lead to arousal. A cross-sectional
observational study was performed involving 49 patients with a clinical diagnosis of non-cys-
tic fibrosis bronchiectasis (NCFB). All patients underwent clinical evaluation, spirometry, and
polysomnography, and were evaluated for the presence of excessive daytime sleepiness
(EDS) and risk of obstructive sleep apnea (OSA). The mean age of the participants was
50.3 ± 13.6 years; 51.1% of patients were male and had a mean body mass index of 23.8 ±
3.4 kg/m2. The mean total sleep time (TST) was 325.15 ± 64.22 min with a slight reduction
in sleep efficiency (84.01 ± 29.2%). Regarding sleep stages, stage 1 sleep and REM sleep
were abnormal. OSA was present in 40.82% of the patients. The mean arousal index was
5.6 ± 2.9/h and snoring was observed in 71.43% of the patients. The oxygen desaturation
index (ODI) was 14.35 ± 15.36/h, mean minimum oxygen saturation (SpO2 nadir) was 83.29
± 7.99%, and mean TST with an SpO2 less than 90% was 30.21 ± 60.48 min. EDS was exhib-
ited by 53.06% of the patients and 55.1% were at high risk of developing OSA. The patients
infected by Pseudomonas aeruginosa had higher apnea-hypopnea indices, ODI, and TST
with SpO2 < 90%, and lower values of SpO2 nadir. Adult patients with clinically stable NCFB,
especially those infected by Pseudomonas aeruginosa, display EDS and a high prevalence
of OSA, associated with considerable oxygen desaturation during sleep.
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Introduction
Bronchiectasis (BCTS) is a chronic disease characterized by irreversible, permanent, and
abnormal dilatation of the bronchi and bronchioles [1–5]. The primary cause of this condition
is repeated cycles of infection and inflammation, leading to progressive destruction of the air-
ways, reduced mucociliary clearance, excessive production of sputum, and a progressive
decline in lung function [6–9].
The prevalence of BCTS is not known definitively; it probably varies significantly among
different populations [10]. It is estimated that there are in the United States of America at least
110,000 adult patients diagnosed with BCTS: 4.2 per 100,000 people between 18 and 34 years
of age, and 272 per 100,000 people aged 75 years or older [11]. An epidemiological study from
Finland suggests an incidence of 2.7 per 100,000 people [12], while in New Zealand, an overall
incidence of 3.7 per 100,000 children was noted [13]. Certain demographic groups, such as
those with little access to health, lower socio-economic status, and high rates of lung infection
in childhood, are at high risk for BCTS [14–15]. In a study of 42,500 admissions to a Brazilian
hospital specializing in lung diseases, 0.4% of patients (170) hospitalized between 1978 and
2001 were diagnosed with BCTS [16]. Another recent study conducted in Germany found an
average annual rate of hospital admissions of patients with BCTS of 9.4 per 100,000 [17].
Sleep disorders have a high prevalence in the general population: they are now considered an
important public health problem, affecting about 45% of the world’s population [18]. A study pub-
lished in 1993 showed that the prevalence of obstructive sleep apnea (OSA) varied from 2% to 3%
in women and 4% to 5% in men [19]. In young adults in the Western world, OSA affects 3% to 7%
of the male population and 2.5% of females [20]. A survey of a representative population of the city
of Sao Paulo showed that 24.8% of men and 9.6% of women had OSA [21]. In patients with chronic
obstructive pulmonary disease (COPD), the prevalence of OSA is 9.5% to 14% [22–24]. Among
patients with cystic fibrosis (CF), about 3.9% meet the criteria for OSA [25]. Among patients with
asthma, the incidence of OSA was 2.51 times greater than that in the control group [26]. In another
study of patients with COPD, 24.7% experienced excessive daytime sleepiness [27].
The research literature has linked certain respiratory diseases with sleep disorders [27–31];
however, the relationship between sleep disorders and BCTS has not been well described.
Recently, two studies that investigated the presence of sleep disorders in patients with BCTS
[32–33] have been published. Both assessed the quality of sleep through specific question-
naires; however, neither study used standard overnight polysomnography (PSG), considered
the gold standard for evaluating the presence of sleep disorders.
To our knowledge, this is the first study to describe the physiological sleep patterns in
patients with non-cystic fibrosis bronchiectasis (NCFB), using PSG. We believe that this study
may contribute to a better understanding of the clinical course of the disease and lead to
potential therapeutic interventions.
We hypothesize that, due to the irreversible dilatation of the bronchi, the presence of spu-
tum, and airflow obstruction, patients with NCFB may be predisposed to hypoxemia during
sleep, or to symptoms that may lead to arousal. The objective of the present study was to
describe physiological variables of sleep in patients with NCFB through PSG, and to stratify
these patients by the risk of OSA and excessive daytime sleepiness (EDS).
Materials and methods
Study design and ethical considerations
A cross-sectional observational study was performed at the Sleep Laboratory in Sao Paulo,
Brazil. The patients were recruited from two BCTS Outpatient Clinics in Sao Paulo, Brazil,
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between April 2013 and March 2016. The study protocol is being published elsewhere
[34].
The design, conduct, and reporting of this study followed the norms of the Strengthening
the Reporting of Observational Studies in Epidemiology (STROBE) statement [35]; they were
compliant with the ethical standards established in the 1961 Declaration of Helsinki (as revised
in Hong Kong in 1989, and in Edinburgh, Scotland in 2000) and with the Regulatory Guide-
lines and Norms for Research Involving Human Subjects of the National Health Board of the
Brazilian Health Ministry, according to Resolution 466/2012. Fig 1 shows the flowchart of the
study.
This study was approved by the Human Research Ethics Committees of Santa Casa de Mis-
ericordia Hospital (Sao Paulo, Brazil; process number 178/2012). All participants signed an
informed consent form. They were allowed to leave the study at any time without negative
consequences.
Eligibility criteria
The patient cohort comprised those diagnosed with BCTS based on the results of high-resolu-
tion chest computerized tomography, which is the gold standard for detecting this disease
[36–37]. Other inclusion criteria were age between 18 and 65 years, use of a long-acting bron-
chodilator (BD), clinical stability for at least one month, and willingness to participate in the
study and provide signed informed consent. Exclusion criteria were BCTS stemming from CF
(i.e., chloride level in sweat > 60 mmol/L), a history of smoking, other lung diseases such as
COPD, asthma and/or other comorbidities that may affect the diagnosis and/or prognosis of
BCTS, or inability of the patient to understand the administered questionnaire.
Patients who had exacerbations of their clinical condition during the medical anamnesis
were eligible to be included in the study if they were clinically stable for one month prior to
their next physician’s appointment; these patients participated in the study at their three-
month follow-up appointment.
Clinical evaluation
Initially, 418 eligible patients with clinical records and confirmed diagnosis of BCTS were
recruited at two reference centers for respiratory diseases in the city of Sao Paulo. Of these, 289
patients who did not meet the inclusion criteria were excluded. Information regarding the
symptoms-specifically, the presence of cough, sputum, hemoptysis, dyspnea, fatigue, wheez-
ing, and rhinosinusitis, the number of exacerbations per year, the drugs administered, comor-
bidities, and etiology of the disease-were collected from 129 medical records. After the data
collection, the clinical evaluation and the analysis of sputum samples for the presence of Pseu-
domonas aeruginosa (PA) in the clinical laboratories attached to the services involved in the
study were performed.
After this step, 79 patients were excluded because they did not fully meet the inclusion crite-
ria, decided not to participate in the study or discontinued the protocol. The remaining 50
patients were referred to the sleep laboratory to perform the physical assessment with the BMI
[38] and neck circumference (NC) [39], pulmonary function tests, PSG overnight tests and
respond to the Berlin questionnaire and The Epworth Sleepiness Scale. These questionnaires
were administered during the morning following PSG exams. Therefore, the presence of snor-
ing and excessive daytime sleepiness were not used as inclusion criteria. The final analysis was
performed with 49 patients due to the exclusion of a patient who presented a PSG with poor
technical quality.
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The Berlin Questionnaire was applied to determine the risk of OSA [40]. This questionnaire
has 10 items organized into three categories: apnea and snoring, daytime sleepiness, and sys-
temic arterial hypertension and obesity. The patients were divided into low risk or high risk of
OSA. To verify the presence of EDS, the simple and self-administered Portuguese language
version of the Epworth Sleepiness Scale (ESS) questionnaire was used [41–43]. This question-
naire addresses situations involving the occurrence of daytime sleepiness during specific activi-
ties of daily living, in adults, by rating their likelihood of experiencing the desire to sleep or
nap, in eight situations, on a scale from 0 to 3.
Fig 1. Flowchart of the study design.
https://doi.org/10.1371/journal.pone.0185413.g001
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Polysomnography
All patients underwent PSG employing the system Somnologica Studio–Embla A10 version
3.1.2 (Medcare Flaga Hs. Medical Devices, Reykjavik, Iceland). The interpretation of the
results was based on the guidelines of the American Academy of Sleep Medicine (AASM).
Patients with an apnea-hypopnea index (AHI) of 5 events per hour of total sleep time were
classified as having OSA. The AHI was calculated as the number of apneas and hypopneas per
hour of total sleep time. OSA was defined as a lack of airflow, or a reduction of 90% in the
airflow signal for at least 10 s, coupled with signs/symptoms (eg, associated sleepiness, fatigue,
insomnia, snoring, subjective nocturnal respiratory disturbance, or observed apnea) or associ-
ated medical or psychiatric disorder (ie, hypertension, coronary artery disease, atrial fibrilla-
tion, congestive heart failure, stroke, diabetes, cognitive dysfunction, or mood disorder).
Obstructive Hypopnea was defined as a discernible drop in airflow of 30% with respect to
the baseline, for at least 10 s, followed by a peripheral oxyhemoglobin desaturation of 4%
[44–46].
Spirometry
All patients underwent spirometry in accordance with the guidelines of the American Thoracic
Society and the European Respiratory Society [47]. Forced vital capacity (FVC), forced expira-
tory volume in the first second (FEV1), and FEV1/FVC ratio were measured before and after
Table 1. Clinical, demographic, and anthropometric characteristics and comorbidities of all enrolled
patients.
Characteristics n = 49
Age, y 50.3 ± 13.6
Male sex, No (%) 27 (51.1)
BMI, kg/m2 23.8 ± 3.4
Cough 48 (97.9)
Dyspnea 39 (79.6)
Lobectomy 13 (26.5)
Hemoptysis 17 (34.7)
Rhinosinusitis 13 (26.5)
Pseudomonas aeruginosa colonization 9 (18.4) ⱡ
Exacerbation frequency in last year 1 (1.00–8.00)
Exacerbation3 times per year 12 (24.5) ⱡ
Causes, No (%)
Post-infective 25 (51.0)
Tuberculosis sequelae 19 (38.8)
Others 5 (10.2)
Comorbidities (%)
Hypertension 17 (34.7)
Chronic cardiac disease 7 (14.3)
Cerebrovascular disease 3 (6.1)
Diabetes mellitus 2 (4.1)
BMI: body mass index; IQR: interquartile range; Kg: kilogram; m2: square meters; SD: standard deviation; y:
years. Data are expressed as mean (±SD), median (IQR) or No. (%).
ⱡ There was no information in the medical record for 2 patients.
https://doi.org/10.1371/journal.pone.0185413.t001
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the use of a short-acting bronchodilator [48]. The spirometry tests were performed using the
KoKo PFT system, version 4.11 (nSpire Health, Inc., Longmont, CO, USA).
Data analysis
Sample size. Because of the paucity of data in the literature regarding the evaluation of
sleep disorders in adult patients with NCFB, a pilot study was carried out to calculate the
appropriate sample size using a prevalence rate of 0.238 for OSA with 90% confidence level,
and a 20% error (i.e., ± 10%). For this study, we determined that a sample size of 49 patients
was required.
Statistical analyses. The Kolmogorov-Smirnov test was carried out first, to determine the
presence or absence of data normality. The data was represented by mean±standard deviation
of normally distributed or median (interquartile interval) for not normally distributed data.
The spirometry values pre-BD and post-BD were compared using the Student t test for paired
samples. For comparisons the presence of PA, azithromycin therapy and exacerbations 3
times a week and PSG variables between individuals with and without OSA, we used, the Stu-
dent t test or the nonparametric Mann-Whitney U test, for quantitative variables. When the
variables were qualitative, the chi-square test or Fisher’s exact test were used, as appropriate.
Correlations between continuous variables with the parameters of PSG were performed using
the Pearson correlation test or Spearman correlation test. For the statistical analysis, we used
the statistical software Statistical Package for Social Sciences 18.01 SPSS (Chicago, IL, USA).
The level of statistical significance was set at 5% for all tests (p< 0.05).
Results
The final sample in this study involved 49 patients. The clinical, demographic, and anthropo-
metric characteristics and comorbidities of all enrolled patients are shown in Table 1. The
majority of NCFB cases (51%) were attributed to post-infection origin. Of the 47 patients (2
patients without a medical record documenting infection), 9 (18.4%) had PA colonization at
baseline, and 12 (24.5%) had exacerbation 3 times per year. Additionally, of the 49 total
patients in the study, 27 were prescribed azithromycin (3 times per week), 6 patients were
using home oxygen therapy, and one patient used benzodiazepines. The spirometric character-
istics of patients diagnosed with NCFB are shown in Table 2. Obstructive breathing patterns
were predominant (59.2%). FEV1% predicted was negatively correlated with snoring time (r =
- 0.361, p = 0.033), oxygen desaturation index (ODI) per hour (r = - 0.299, p = 0.054) and total
sleep time (TST) with peripheral capillary oxygen saturation (SpO2)< 90% (r = - 0.300,
p = 0.036), as shown in Fig 2. No significant correlations were found between FEV1% predicted
and any other sleep variables.
PSG physiological variables, ESS scores, and Berlin Questionnaire results for all patients are
shown in Table 3. The values referring to physiological sleep variables were obtained through
Overnight PSG recordings and compared to normal values for the adult population considered
in the scientific literature [49].
The 49 patients were divided into 2 groups according to the presence or absence of OSA.
Comparison of both groups (OSA vs. non-OSA) demonstrated significant differences in NC,
SpO2 nadir nocturnal, ODI/h, TST with SpO2 < 90%, PA colonization, and high risk of devel-
oping OSA (Table 4).
In the OSA group, NC, ODI/h, TST with SpO2 < 90%, and PA colonization were higher
and SpO2 nadir nocturnal was lower than the corresponding values in the non-OSA group.
Patients receiving azithromycin therapy (3 times per week) had higher TST (345.10 ± 57.82
min vs. 300.66 ± 64.4 min, p = 0.027) and sleep efficiency (88.63 ± 11.62% vs. 78.34 ± 11.62%,
Obstructive sleep apnea in non-cystic fibrosis bronchiectasis
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p = 0.007). Since patients with exacerbation 3 times per year had higher snoring time
(150.54 ± 115.64 min vs. 59.84 ± 65.65 min, p = 0.010), and they had lower SpO2 nadir noctur-
nal (79.83 ± 7.83% vs. 84.40 ± 7.94%, p = 0.050) and TST with SpO2 < 90% (12.98 ± 31.40 min
vs. 67.0 ± 84.01 min, p = 0.010).
Fig 3 shows a significant relationship between the presence of PA and AHI, ODI, and TST
with SpO2 < 90%. The patients with NCFB with PA had higher AHI, ODI, and TST with SpO2
< 90%, and lower SpO2 nadir.
Discussion
To our knowledge, this is the first study to describe physiological sleep variables in adult
patients with NCFB, using the gold standard for evaluating sleep disorders—PSG. In our
study, the prevalence of NCFB was higher in male patients; the mean BMI value demonstrates
that these patients were within the ideal weight range.
Table 2. Spirometric variables of patients with non-cystic fibrosis bronchiectasis (n = 49).
Pre-BD Post-BD P value
FEV1, L 1.56 ± 0.64 1.66 ± 0.67 <0.001
FEV1% predicted 52.56 ± 19.35 57.39 ± 21.48 <0.001
FVC, L 2.49 ± 0.75 2.58 ± 0.75 0.010
FVC % predicted 68.01 ± 17.76 70.93 ± 17.91 0.002
FEV1/FVC % 68.46 ± 16.63 68.27 ± 18.17 ns
BD. Bronchodilator; FEV1: forced expiratory volume in the first second; FVC: forced vital capacity; L: liters; NS: no significant difference; SD: standard
deviation. Data are expressed as mean (± SD) or No. (%).
https://doi.org/10.1371/journal.pone.0185413.t002
Fig 2. Correlation between FEV1 and sleep parameters. FEV1: forced expiratory volume in the first
second; h: hours; min: minutes; ODI: oxygen desaturation index; OSA: obstructive sleep apnea; SD: standard
deviation; SpO2mean: mean peripheral capillary oxygen saturation.
https://doi.org/10.1371/journal.pone.0185413.g002
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The lung function of these patients with NCFB displayed predominance of obstructive lung
disease, similar to that observed in the literature [50]. The majority had moderate severity, and
were, on average, responsive to the use of BD. The finding of air flow limitation in the presence
of bronchial dilatation can be tentatively ascribed to the fact that the dilated bronchi show
inflammation, and are constantly obstructed by the presence of intraluminal secretions, with
consequent reduction in lumen diameter [5].
Regarding sleep patterns, it was observed that, in general, the patients with NCFB slept less,
and showed a discrete alteration in sleep efficiency and fragmented sleep architecture, with an
increase in non-rapid eye movement (NREM) stage 1 sleep and reduction in rapid eye move-
ment (REM) sleep. Young adult patients with CF exhibit sleep efficiency close to that found in
this study, being 85.2% to 87.1% [28]. REM sleep is also reported to be reduced in CF patients,
although the studies were performed in children [51]. The presence of snoring was also
observed in 71.43% of the studied population; a higher percentage than that in patients with
asthma and COPD [52–53]. Although the main symptoms in the patients with NCFB are the
presence of cough and sputum, only 14.29% of the patients showed arousal—higher than that
found in patients with CF [54], although lower than that recorded in a recent study involving
COPD subjects [55].
Table 3. Polysomnographic physiological variables, Epworth Sleepiness Scale score and Berlin Questionnarie results in patients with non-cystic
fibrosis bronchiectasis (n = 49).
Variables Values Reference values
TST (min) 325.15 ± 64.22 300–360
Sleep Efficiency (%) 84.01 ± 14.16 > 85%
Sleep Stadiums
E1 (%TST) 9.97 ± 8.45 3–5
E2 (%TST) 44.72 ± 12.11 45–50
E3(%TST) 22.65 ± 15.08 18–20
REM (%TST) 17.33 ± 9.05 20–25
Snoring presence (%) 71.43 -
Snoring time (TST) (min) 80.63 ± 89.02 -
Arousals index (events/h) 11.02 ± 10.76 > 15
Arousals presence, (%) 14.29 -
AHI (events/h) 7.63 ± 11.53 AHI < 5
AHI, severity of OSA
Mild (%) 24.49 AHI 5–15
Moderate (%) 12.24 AHI 16–30
Severe (%) 4.08 AHI > 30
ODI/h 14.35 ± 15.36 -
SpO2mean (%) 93.76 ± 2.71 > 90%
SpO2nadir (%) 83.29 ± 7.99 > 90%
TST<SpO2 90% (min) 30.21 ± 60.48 -
ESS score 10.65 ± 5.97 < 10
Excessive daytime sleepiness (ESS 10) (%) 26 (53.06) -
Berlin Questionnaire (high risk for OSA) (%) 27 (55.10) Low risk
Data are expressed as mean (± SD), or No. (%). AHI: apnea-hypopnea index; ESS: Epworth sleepiness scale; E1: sleep stage 1; E2: sleep stage 2; E3:
sleep stage 3; h: hours; min: minutes; ODI: oxyhemoglobin desaturation index; OSA: obstructive sleep apnea; REM: rapid eyes movement; SD: standard
deviation; SpO2mean: mean oxyhemoglobin saturation; SpO2nadir: minimum oxyhemoglobin saturation; TST: total sleep time; EDS: Excessive daytime
sleepiness.
https://doi.org/10.1371/journal.pone.0185413.t003
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However, the presence of oxygen desaturation was observed in the majority of the patients:
38.7% of the patients had an SpO2 nadir < 85%. The mean ODI was 14.35 ± 15.36/h and the
average SpO2 nadir was 83.29 ± 7.99%, the mean TST with SpO2 < 90% being 30.21 ± 60.48
min, representing around 9% of the TST. Milross et al. [31] found, in patients with CF, an
average SpO2 nadir nocturnal of 82.5%, which is corroborated by the current study.
Table 4. Comparison of clinical characteristics of OSA and no-OSA non-cystic fibrosis bronchiectasis patients.
Characteristics
OSA
(n = 20)
no-OSA
(n = 29)
P value
Age (y) 50.55 ± 14.49 50.10 ± 13.22 ns
Male sex, % 80.0 37.9 0.004
BMI (kg/m2) 24.56 ± 2.30 22.51 ± 3.86 ns
Neck circumference (cm) 37.80 ± 2.86 34.95 ± 3.30 0.026
VEF1% predicted 49.15 ± 19.39 55.89 ± 19.56 ns
SpO2 mean nocturnal 93.02 ± 2.65 94.28 ± 2.68 ns
SpO2 nadir nocturnal 84 (52.0–88.0) 87 (72–95) 0.002
ODI/ h 16.4 (4.5–76.7) 6.2 (0.8–20.2) 0.001
TST < SpO2 90% (min) 5.4 (0.1–177.0) 0.4 (0–222.2) 0.005
Pseudomonas aeruginosa 7 (35.0) 2 (7.4)ⱡ 0.026
ESS score 11.07 ± 6.16 10.43 ± 5.97 ns
Exacerbation frequency in last year 1.0 (0–7) 1.0 (0–3) ns
Exacerbation3 times per year 6 (30.0) 6 (22.2)ⱡ ns
Berlin questionnaire (high risk for OSA) 15 (75.0) 11 (37.9) 0.011
AHI: apnea-hypopnea index; ESS: Epworth sleepiness scale; FEV1: forced expiratory volume in the first second; h: hours; IQR: interquartile range; min:
minutes; ns: no significant difference; ODI: oxyhemoglobin desaturation index; OSA: obstructive sleep apnoea; SD: standard deviation; SpO2mean: mean
oxyhemoglobin saturation; SpO2nadir: minimum oxyhemoglobin saturation; TST: total sleep time; y: years. Data are expressed as mean (± SD), median
(IQR) or percentile (%).
ⱡ There was no information in the medical record for 2 patients.
https://doi.org/10.1371/journal.pone.0185413.t004
Fig 3. PSG parameters according to presence of Pseudomonas aureginosa. Each box shows median
(solid black line), interquartile range (solid box), and extreme values. p < 0.05 was considered statistically
significant.
https://doi.org/10.1371/journal.pone.0185413.g003
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The presence of cough and accumulation of secretion would result in hyperventilation, ven-
tilatory disorders, and gas exchange alterations, contributing to hypoxemia, which occurs in
patients with COPD [56]. When we analyzed the presence of OSA in the phases of REM sleep
(5.7 ± 8.3) and NREM sleep (3.6 ± 9.3) and the presence of hypopnea in the REM sleep
(9 ± 10.8) and NREM sleep (2.8 ± 3.9) we can observe the presence of both events, apnea and
hypopnea in the two phases of sleep. This finding justifies the presence of significant SpO2
nadir, ODI, and TST with SpO2 < 90% values when comparing OSA and no-OSA patients,
reinforcing the deleterious effect of OSA in this population. The fact that these variables pres-
ent a significant difference when compared to OSA and no-OSA patients demonstrates the
effect of obstructive events on nocturnal oxyhemoglobin saturation and not only the effect due
to structural lung disease.
Another possible explanation for this reduction in SpO2 is the presence of OSA in this pop-
ulation, as described in this study and detailed in Table 4: there are statistically significant dif-
ferences in SpO2 nadir, ODI, and TST with SpO2< 90% depending on whether there is OSA
or not. This finding is very important because Onen et al. [57] correlated hypoxemia with mor-
tality. Another possible explanation for this reduction in SpO2 is the presence of OSA in this
population, as described in this study and detailed in Table 4: there are statistically significant
differences in SpO2 nadir, ODI, and TST with SpO2 < 90% depending on whether there is
OSA or not. This finding is very important because Onen et al. [57] correlated hypoxemia with
mortality.
Through assessing the ESS, it was found that 53.1% of the patients reported EDS, which is a
higher percentage than that found in the general population [58], in adults with CF [59],
COPD [27], and in a recent study with stable adult patients with BCTS [33], in which 31.9%
exhibited EDS. It is noteworthy that the FEV1% predicted was lower in our study and that
patients with NCFB showed a higher EDS risk, associated with the presence of cough and spu-
tum [60], and were more commonly found in those with OSA.
As in a recent study performed with asthma patients [26], a high risk of OSA was observed
in our study on NCFB. The concordance between the prevalence of high risk of OSA, assessed
through the Berlin Questionnaire, and the prevalence of OSA, assessed through PSG, was con-
firmed by the significant difference found between the groups with and without OSA.
Katz et al [61] reported in their study that around 50% of patients with CF showed sleep dis-
orders. In patients with BCTS, Erdem et al. [32] described 37% of children with CF exhibiting
sleep disorders, while Gao et al [33] reported that 56.9% of stable adults with BCTS also dem-
onstrated sleep disorders. Both did not directly assess the presence of OSA: they used very spe-
cific sleep questionnaires. In our study, utilizing PSG, the presence of OSA in clinically stable
adult patients with NCFB was 40.28% above that encountered in the general population [20–
21] and in other respiratory diseases [23, 25, 26]. Only one recent study, in patients with
COPD, performed in Singapore, presented a higher OSA prevalence than that found in our
study [55].
While comparing some risk factors for OSA, according to AASM [46], by regarding those
with or without OSA, we verified the statistically significant difference regarding male gender
and NC.
The neck circumference values presented a significant difference when compared to the
OSA and non-OSA groups. However, when comparing the mean values obtained in the popu-
lation of this study with the reference values proposed in the literature (41 cm for women and
43 cm for men), it can be observed that these are below the cut-off values for the Presence of
OSA. The BMI values did not present significant difference between the two groups and when
compared to the reference values proposed by the WHO it was observed that they are under-
weight, clinical characteristic of the disease.
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When we verified the presence of rhinosinusitis in the patients involved in this study, it was
observed that only 13 patients (26.5%) presented complaints. In these patients, the mean value
of AHI was 5.8 events per hour. Three patients presented mild AHI, three had moderate AHI
and the other patients (7 patients) presented no OSA.
Patients with chronic nasal and sinus inflammation usually have nonspecific bronchial
hyperresponsiveness, suggesting a neural reflex. Postnasal drainage of nasal inflammatory
mediators during sleep in patients with sinus disease may also increase lower airway respon-
siveness. [62] We could think that the sinus disease would impact on nasal patency and could
tip the people toward higher likelihood of OSA. However, according to the data obtained in
this study and according to the lack of scientific studies about a possible association, we can
not consider the presence of rhinosinusitis as a risk factor for OSA.
The FEV1% predicted did not show a statistically significant difference depending on the
presence or absence of OSA, although in the OSA group the FEV1 value was < 50% of pre-
dicted, which is a predictor of the severity of BCTS [63].
Another severity predictor, the presence of PA, was higher in patients with OSA (p = 0.026).
Besides that, patients with NCFB that were colonized with PA showed higher AHI and greater
oxygenation changes, with higher ODI and TST with SpO2 < 90% and lower SpO2 minimum.
Probably the mechanism entails worsening of pulmonary function and greater production of
secretions, caused by colonization with this bacterium [5]. We can hypothesize that the presence
of PA, by provoking systemic and airways inflammation—in addition to being responsible for
the worsening of pulmonary function [64] could lead to apnea and hypopnea, given that
patients with OSA normally show airways inflammation.
Additionally, patients with 3 exacerbations per year, also considered a BCTS severity pre-
dictor, exhibit longer snoring periods, worse SpO2 nadir and higher TST with SpO2 < 90%.
Regarding all the patients with NCFB, 55.1% were receiving drug treatment with azithromycin
(3 times a week), indicated as immunomodulatory and anti-inflammatory therapy [65–67]. In
the group of patients with 3 exacerbations per year, higher TST and sleep efficiency were
observed, probably due to the reduction in secretions and anti-inflammatory effects.
We believe that the results of this study draw the attention of the scientific community to
the importance of research into the presence of sleep-disordered breathing in patients with
BCTS and the possible indication for treatment of these patients with non-invasive ventilator
support.
Conclusion
Adult patients with clinically stable NCFB, especially those infected with PA, exhibit EDS and
high prevalence of OSA, associated with considerable oxygen desaturation during sleep.
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